Of available focal therapies, the speaker listed cryoablation and laser ablation. In order to evaluate the efficacy and safety of MR-guided cryoablation in this patient population, Sotoudehnia and colleagues enrolled 90 patients between September and September The patients had a mean age of 73 years and had previously received radiation therapy or prostatectomy. Sotoudehnia stated that their team carefully monitored ice ball expansion via magnetic resonance imaging MRI to ensure target coverage.
Sotoudehnia then detailed a subgroup analysis carried out by their team, evaluating alternative treatments and their recurrence rates in this patient population. The analysis showed that in-field recurrence rates were highest when patients were treated with combined prostatectomy and radiation Two of these patients had received prostatectomy and radiation combined, while one patient had received radiation alone.
Further, another patient with a history of prostatectomy reportedly experienced vesicorectal fistula, Sotoudehnia explained. Sotoudehnia summarised that their data shows cryoablation to be effective in reducing PSA in patients with recurrent prostate cancer. The primary safety endpoint is the composite rate of major adverse events MAEs within 48 hours post-procedure. Surmodics has announced the successful early clinical use of its Pounce XL thrombectomy system.
A press release notes that Surmodics Pounce thrombectomy systems are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce XL thrombectomy system is indicated for use in vessels ranging from 5. With hospitals under growing pressure to reduce costs, we believe the standalone Pounce thrombectomy platform may help reduce the need for hospitalisations and follow-up procedures.
With over 20, procedures now completed and a growing library of clinical data, Serranator has proven itself to be a valuable tool in this fight. The Serranator SL-PRO is a purpose-built tool for pedal intervention, and with it, the Serranator product family can now treat from hip to toe. New data from a prospective, multicentre randomised controlled trial show similar hepatic progression-free survival hPFS using bland transarterial embolization TAE or transarterial chemoembolization TACE when treating neuroendocrine tumour metastases in the liver.
